|
1
|
Gerlinger M, Rowan AJ, Horswell S, et al:
Intratumor heterogeneity and branched evolution revealed by
multiregion sequencing. N Engl J Med. 366:883–892. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Baldus SE, Schaefer KL, Engers R, Hartleb
D, et al: Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA
mutations in primary colorectal adenocarcinomas and their
corresponding metastases. Clin Cancer Res. 16:790–799. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marusyk A and Polyak K: Tumor
heterogeneity: causes and consequences. Biochim Biophys Acta.
1805:105–117. 2010.PubMed/NCBI
|
|
4
|
De Roock W, Piessevaux H, De Schutter J,
et al: KRAS wild-type state predicts survival and is associated to
early radiological response in metastatic colorectal cancer treated
with cetuximab. Ann Oncol. 19:508–515. 2008.PubMed/NCBI
|
|
5
|
Jönsson M, Ekstrand A, Edekling T, et al:
Experiences from treatment-predictive KRAS testing; high mutation
frequency in rectal cancers from females and concurrent mutations
in the same tumor. BMC Clin Pathol. 9:82009.PubMed/NCBI
|
|
6
|
Moerkerk P, Arends JW, van Driel M, et al:
Type and number of Ki-ras point mutations relate to stage of human
colorectal cancer. Cancer Res. 54:3376–3378. 1994.PubMed/NCBI
|
|
7
|
Sameer AS, ul Rehman S, Pandith AA, et al:
Molecular gate keepers succumb to gene aberrations in colorectal
cancer in Kashmiri population, revealing a high incidence area.
Saudi J Gastroenterol. 15:244–252. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sanger F, Nicklen S and Coulson AR: DNA
sequencing with chain-terminating inhibitors. Proc Natl Acad Sci
USA. 74:5463–5467. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lièvre A, Bachet JB, Le Corre D, et al:
KRAS mutation status is predictive of response to cetuximab therapy
in colorectal cancer. Cancer Res. 66:3992–3995. 2006.PubMed/NCBI
|
|
10
|
Amado RG, Wolf M, Peeters M, et al:
Wild-type KRAS is required for panitumumab efficacy in patients
with metastatic colorectal cancer. J Clin Oncol. 26:1626–1634.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
et al: K-ras mutations and benefit from cetuximab in advanced
colorectal cancer. N Engl J Med. 359:1757–1765. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Al-Mulla F, Going JJ, Sowden ET, et al:
Heterogeneity of mutant versus wild-type Ki-ras in primary and
metastatic colorectal carcinomas, and association of codon-12
valine with early mortality. J Pathol. 185:130–138. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Albanese I, Scibetta AG, Migliavacca M, et
al: Heterogeneity within and between primary colorectal carcinomas
and matched metastases as revealed by analysis of Ki-ras and p53
mutations. Biochem Biophys Res Commun. 325:784–791. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mancuso A, Sollami R, Recine F, et al:
Patient with colorectal cancer with heterogeneous KRAS molecular
status responding to cetuximab-based chemotherapy. J Clin Oncol.
28:e756–e758. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lamy A, Blanchard F, Le Pessot F, et al:
Metastatic colorectal cancer KRAS genotyping in routine practice:
results and pitfalls. Mod Pathol. 24:1090–1100. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bouchahda M, Karaboué A, Saffroy R, et al:
Acquired KRAS mutations during progression of colorectal cancer
metastases: possible implications for therapy and prognosis. Cancer
Chemother Pharmacol. 66:605–609. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Andreyev HJ, Norman AR, Cunningham D, et
al: Kirsten ras mutations in patients with colorectal cancer: the
multicenter ‘RASCAL’ study. J Natl Cancer Inst. 90:675–684.
1998.
|
|
18
|
Macedo MP, Andrade Lde B, Coudry R, et al:
Multiple mutations in the Kras gene in colorectal cancer: review of
the literature with two case reports. Int J Colorectal Dis.
26:1241–1248. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Perou CM, Sørlie T, Eisen MB, et al:
Molecular portraits of human breast tumours. Nature. 406:747–752.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sørlie T, Perou CM, Tibshirani R, et al:
Gene expression patterns of breast carcinomas distinguish tumor
subclasses with clinical implications. Proc Natl Acad Sci USA.
98:10869–10874. 2001.PubMed/NCBI
|
|
21
|
Fialkow PJ: Clonal origin of human tumors.
Annu Rev Med. 30:135–143. 1979. View Article : Google Scholar
|
|
22
|
Winder T, Mündlein A, Rhomberg S, et al:
Different types of K-Ras mutations are conversely associated with
overall survival in patients with colorectal cancer. Oncol Rep.
21:1283–1287. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Richman SD, Chambers P, Seymour MT, et al:
Intra-tumoral heterogeneity of KRAS and BRAF mutation status in
patients with advanced colorectal cancer (aCRC) and
cost-effectiveness of multiple sample testing. Anal Cell Pathol
(Amst). 34:61–66. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Spitzner M, Emons G, Kramer F, et al: A
gene expression signature for chemoradiosensitivity of colorectal
cancer cells. Int J Radiat Oncol Biol Phys. 78:1184–1192. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pedicini P, Nappi A, Strigari L, et al:
Correlation between EGFr expression and accelerated proliferation
during radiotherapy of head and neck squamous cell carcinoma.
Radiat Oncol. 7:1432012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pedicini P, Caivano R, Jereczek-Fossa BA,
et al: Modelling the correlation between EGFr expression and tumor
cell radiosensitivity, and combined treatments of radiation and
monoclonal antibody EGFr inhibitors. Theor Biol Med Model.
9:232012. View Article : Google Scholar
|
